Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Poseltinib - Hanmi Pharmaceutical

Next Previous
Search
Drug Profile

Poseltinib - Hanmi Pharmaceutical

Alternative Names: HM 71224; LY 3337641; NB-02 - NOBO Medicine

Latest Information Update: 24 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Eli Lilly and Company; Hanmi Pharmaceutical; NOBO Medicine
  • Class Antirheumatics; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Lymphoma
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 24 Dec 2024 https://325f0582.isolation.zscaler.com/profile/f1651b6c-5a7a-4e25-a61a-66f8cd23da60/zia-session/?tenant=2c2f6c39ed9e&region=bom&controls_id=e9deed71-abd6-47d6-beda-3be9a5b22af8&user=029860c8f97377a95a96735dfa6c1ffef3f348a3b26af33788a630663cd8a3d5&original_url=https%3A%2F%2Fwww.nobomedicine.com%2F%3Fpost_type%3Dnews&key=sh-1&hmac=4e7729c259a254c7adc380855fa1be2c77d135c351f3c224e3eba06850a0e19e -According to NOBO medicine pipeline, Hanmi and NOBO Medicine had a technology transfer deal between them but as there is no R found, only based on pipeline, org T was updated and this RDI was linked to the given trial (NCT06737250) - Trial initiation information added
  • 25 Nov 2024 Phase-II clinical trials in Lymphoma (Second-line therapy or greater, Combination therapy) in South Korea (PO) (NCT06737250)
  • 08 Jun 2023 Efficacy and adverse event data from phase II trial in Diffuse large B cell lymphoma presented at the 28th Congress of the European Haematology Association (EHA-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top